Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging

European Journal of Endocrinology

Volumn 135, Issue 4, 1996, Pages 407-412

  Ghigo, E ^a   Arvat, E ^a   Gianotti, L ^a   Grottoli, S ^a   Rizzi, G ^b   Ceda, G P ^c   Boghen, M F ^d   Deghenghi, R ^e   Camanni, F ^a,f  

^a UNIVERSITY OF TURIN   (Italy)

^b Hospital of Saluzzo   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d Pharmacia PH   (Italy)

^e Ardana   (France)

^f MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HEXARELIN; SERMORELIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; AGING; ARTICLE; CONTROLLED STUDY; GROWTH HORMONE RELEASE; HORMONE SENSITIVITY; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL;

EID: 0029950441     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1350407     Document Type: Article

References (39)

1. Ghigo E, Arvat E, Goffi S, Bellone J, Nicolosi M, Procopio M, et al. Neural control of growth hormone secretion in aged humans. In: Muller EE, Cocchi D, Locatelli V, editors. Growth hormone and somatomedins during lifespan. Berlin: Springer Verlag, 1993: 275-87
2. Corpas E, Harman SM, Blackman S. Human growth hormone and human aging. Endocr Rev 1993;14:20-39
3. Rudman D, Kutner MH, Rogers M, Lubin MF, Fleming GA, Bain RP. 1981 Impaired growth hormone secretion in the adult population. J Clin Invest 1981;67:1361-9
4. Rudman D, Feller AC, Nagraj HS. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6
5. Sonntag WE, Forman LJ, Miki N. Effects of CNS active drugs and somatostatin antiserum on growth hormone release in young and old male rats. Neuroendocrinology 1981;33:73-8
6. Weherenberg WB, Ling N. The absence of an age-related change in the pituitary response to growth hormone-releasing factors in rats. Neuroendocrinology 1983;37:463-4
7. Morimoto N, Kawakami F, Makino S, Chihara K, Hasegawa M, Ibata Y. Age-related changes in growth hormone releasing factor and somatostatin in the rat hypothalamus. Neuroendocrinology 1988;47:459-64
8. Ge F, Tsagarakis S, Rees LH, Besser GM, Grossman A. Relationship between growth hormone-releasing hormone and somatostatin in the rat: effects of age and sex on content and in-vitro release from hypothalamic explants. J Endocrinol 1989;123:53-8
9. Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, et al. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. J Clin Endocrinol Metab 1990;71:1481-5
10. Ghigo E, Goffi S, Arvat E, Imperiale E, Boffano GM, Valetta MR, et al. A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging. J Endocrinol Invest 1992; 15:665-70
11. Ghigo E. Neurotransmitter control of growth hormone secretion: In: de la Cruz LF, editor. Growth hormone and somatic growth. Amsterdam: Excerpta Medica, 1992:103-36
12. De Gennaro V, Zoli M, Cocchi D. Reduced growth hormone releasing factor (GHRH)-like immunoreactivity and GHRH gene expression in hypothalamus of aged rats. Peptides 1989;10:705-8
13. Ceda GP, Valenti G, Butturini U, Hoffman AR. Diminished pituitary responsiveness to growth hormone-releasing factor in aging male rats. Endocrinology 1986;2109-14
14. Corpas E, Harman M, Pineyro MA, Roberson R, Blakman R. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992;75:530-5
15. Bowers CY, Veeraragavan K, Sethumadhavan K. Atypical growth hormone releasing peptides. In: Bereu BB, Walker RF, editors. Growth hormone II, basic and clinical aspects. New York: Springer-Verlag, 1993:203-22
16. Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, et al. Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man. J Clin Endocrinol Metab 1994;78:693-8
17. Smith RG, Cheng K, Schoen WR, et al. A nonpeptidyl growth hormone secretagogue. Science 1993;260:1640-3
18. Ghigo E, Arvat E, Rizzi G, Bellone J, Nicolosi M, Boffano GM, et al. Arginine enhances the growth hormone(GH)-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration. J Endocrinol Invest 1994;17: 157-62
19. Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaets V, Deghenghi R, et al. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. J Clin Endocrinol Metab 1995;78: 693-8
20. Ghigo E, Arvat E, Rizzi G, Goffi S, Grottoli S, Mucci M, et al. Growth hormone-releasing activity of growth hormone-releasing peptide is maintained after short-term oral pretreatment with hexapeptide in normal aging. Eur J Endocrinol 1994;131:499-503
21. Grossman A, Savage MO, Lytras N, et al. Response to analogues of GH-releasing hormone in normal subjects and in growth hormone deficient children and young adults. Clin Endocrinol 1984;21:321-9
22. Huhn WC, Hartman ML, Pezzoli SS, Thorner MO. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab 1993;76:1202-8
23. Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY, Barkan AL. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab 1993;77:1641-7
24. DeBell WK, Pezzoli SS, Thorner MO. Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: partial response attenuation. J Clin Endocrinol Metab 1991;72: 1312-6
25. 2 in the rat. Endocrinology 1985;117:1441-7
26. 2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men. Endocrinol Jpn 1991;38:15-21
27. Codd EE, Shu AYL, Walker RF. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 1989;28:1139-44
28. Veeraragavan K, Sethumadhavan K, Bowers CY. Growth hormone-releasing peptide (GHRP) binding to porcine anterior-pituitary and hypothalamic membranes. Life Sci 1992;50:1149-55
29. Guillame V, Magnan E, Cataldi M, Dutour A, Sauze N, Conte-Devolx B, et al. Growth hormone (GH)-releasing hormone secretion stimulated by a new GH-releasing hexapeptide in sheep. Endocrinology 1994;135:1073-6
30. Dickson SL, Leng G, Robinson ICAF. Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurones. Neurosci Lett 1993;53:303-7
31. Conley LK, Teik JA, Deghenghi R. Imbimbo BP, Giustina A, Locatelli V. Mechanism of action of hexarelin and GHRP-6: analysis of the involvement of GHRH and somatostatin in the rat. Neuroendocrinology 1995;61:44-50
32. Goth MI, Lyons CE, Canny BJ, Thorner MO. Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pitutary receptors. Endocrinology 1992:130:939-44
33. 2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3′,5′-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology 1989;124: 2791-8
34. Fairhall KM, Mynett A, Robinson ICAF. Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. J Endocrinol 1995;144:555-60
35. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS. Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990;70:975-82
36. Arvat E, Gianotti L, Di Vito L. Imbimbo BP. Lenaerts V, Deghenghi R, et al, Modulation of growth hormone-releasing activity of hexarelin in man. Neuroendocrinology 1995;61:51-6
37. Penalva A, Carballo A, Pombo M, Casanueva FF, Dieguez C. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglicemia on GHRP-6 induced GH secretion in man. J Clin Endocrinol Metab 1993;76:168-71
38. Maccario M, Avat E. Procopio M, Gianotti L, Grottoli S, Imbimbo BP, et al. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. Metabolism 1995;44:134-8
39. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 1993;391-3